The Food and Drug Administration (FDA) last week amended emergency use authorizations for Pfizer and Moderna’s COVID-19 vaccines to allow for the use of a third, additional dose for certain immunocompromised individuals, specifically for “solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.”
This content is restricted to members.
